Person:
TÜRK, HACI MEHMET

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
HACI MEHMET
Last Name
TÜRK
Name
Email Address
Birth Date

Filters

2020 - 202447
Reset filters

Settings

Start date: 2020 × End date: 2024 ×

Search Results

Now showing 1 - 10 of 47
  • No Thumbnail Available
    PublicationMetadata only
    Relationship between KRAS mutation and diffusion weighted imaging in colorectal liver metastases; Preliminary study.
    (2020-02-25T00:00:00Z) Türk, HM; Gültekin, MEHMET ALİ; Uysal, Ö; Beşiroğlu, M; Yilmaz, TF; Yurtsever, I; GÜLTEKİN, MEHMET ALİ; TÜRK, HACI MEHMET; TOPRAK, HÜSEYİN; YURTSEVER, İSMAİL; YILMAZ, TEMEL FATİH; SHARIFOV, RASUL; UYSAL, ÖMER
    Purpose: We aimed to investigate whether there are any differences in apparent diffusion coefficient (ADC) values obtained from colorectal liver metastases (CRLM) according to Kirsten rat sarcoma (KRAS) gene mutation status.
  • Thumbnail Image
    PublicationOpen Access
    Report of a Case of Signet Ring Carcinoma Presenting as Gastric Mucosal Thickening: A Diagnostic Dilemma
    (2021-01-01T00:00:00Z) Karatoprak, Cumali; Akçakaya, Adem; Şentürk, Hakan; Çoban, Ganime; Şahin, Nurhan; Türk, Hacı Mehmet; KARATOPRAK, CUMALİ; AKÇAKAYA, ADEM; ŞENTÜRK, HAKAN; ÇOBAN, GANİME; ŞAHİN, NURHAN; TÜRK, HACI MEHMET
    The number of cancer cases has been increasing worldwide. Early diagnosis and tumor resection remain as the most effective treatments for gastric cancer. However, early diagnosis is not always possible as it is frequently not possible to make treatment decisions without pathologic diagnosis in patients with clinically suspected cancer. This causes delays in diagnosing cancer. We presented a 58 years old woman with gastric signet ring cell carcinoma that could not be diagnosed despite using four different methods of stomach biopsies. We aimed to emphasize that despite the use of advanced methods, if clinical cancer in non-diagnosed cases is suspected, we should be more aggressive for early diagnosis.
  • No Thumbnail Available
    PublicationMetadata only
    Clinicopathological features of gastroenteropancreatic neuroendocrine neoplasms: a retrospective single-center experience
    (2021-03-01T00:00:00Z) ŞEKERCİ, ABDÜSSELAM; TÜRK, HACI MEHMET; DEMİR, Tarık; ŞEKER, Mesut; AKÇAKAYA, Adem; ARICI, Dilek Sema; ŞEKERCİ, ABDÜSSELAM; TÜRK, HACI MEHMET; DEMİR, TARıK; ŞEKER, MESUT; AKÇAKAYA, ADEM; ARICI, DILEK SEMA
  • Thumbnail Image
    PublicationOpen Access
    Diagnostic performance of apparent diffusion coefficient values for the differentiation of intrahepatic cholangiocarcinoma from gastrointestinal adenocarcinoma liver metastases
    (2021-12-22T00:00:00Z) Yilmaz, TEMEL FATİH; Gultekin, Mehmet Ali; Turk, Hacı Mehmet; Cesme, Dilek Hacer; Besiroglu, Mehmet; Simsek, Melih; Toprak, Huseyin; Alkan, ALPAY; YILMAZ, TEMEL FATİH; TÜRK, HACI MEHMET; ÇEŞME, DİLEK HACER; ŞİMŞEK, MELİH; ALKAN, ALPAY; TOPRAK, HÜSEYİN
    Background: We aimed to investigate whether there is a difference between intrahepatic cholangiocarcinoma (IHCC) and liver metastases of gastrointestinal system (GIS) adenocarcinoma in terms of apparent diffusion coefficient (ADC) values. Patients and methods: From January 2018 to January 2020, we retrospectively examined 64 consecutive patients with liver metastases due to gastrointestinal system adenocarcinomas and 13 consecutive IHCC in our hospital's medical records. After exclusions, fifty-three patients with 53 liver metastases and 10 IHCC were included in our study. We divided the patients into two groups as IHCC and liver metastases of GIS adenocarcinoma. For mean apparent diffusion coefficient (ADCmean) values, the region of interests (ROI) was placed in solid portions of the lesions. ADCmean values of groups were compared. Results: The mean age of IHCC group was 62.50 ± 13.49 and mean age of metastases group was 61.15 ± 9.18. ADCmean values were significantly higher in the IHCC group compared to the metastatic group (p < 0.001). ROC curves method showed high diagnostic accuracy (AUC = 0.879) with cut-off value of < 1178 x 10-6 mm2/s for ADCmean (Sensitivity = 90.57, Specificity = 70.0, positive predictive value [PPV] = 94.1, negative predictive value [NPV] = 58.3) in differentiating adenocarcinoma metastases from IHCC. Conclusions: The present study results suggest that ADC values have a potential role for differentiation between IHCC and GIS adenocarcinoma liver metastases which may be valuable for patient management.
  • Thumbnail Image
    PublicationOpen Access
    Diffusion Tensor Imaging Can Discriminate the Primary Cell Type of Intracranial Metastases for Patients with Lung Cancer.
    (2021-03-04T00:00:00Z) Bilgin, Sabriye Sennur; Gultekin, Mehmet Ali; Yurtsever, Ismail; Yilmaz, Temel Fatih; Cesme, Dilek Hacer; Bilgin, Melike; Topcu, Atakan; Besiroglu, Mehmet; Turk, Haci Mehmet; Alkan, ALPAY; Bilgin, Mehmet; GÜLTEKİN, MEHMET ALİ; YURTSEVER, İSMAİL; YILMAZ, TEMEL FATİH; ÇEŞME, DİLEK HACER; TÜRK, HACI MEHMET; ALKAN, ALPAY; BİLGİN, MEHMET
    Purpose: Histopathological differentiation of primary lung cancer is clinically important. We aimed to investigate whether diffusion tensor imaging (DTI) parameters of metastatic brain lesions could predict the histopathological types of the primary lung cancer. Methods: In total, 53 patients with 98 solid metastatic brain lesions of lung cancer were included. Lung tumors were subgrouped as non-small cell carcinoma (NSCLC) (n = 34) and small cell carcinoma (SCLC) (n = 19). Apparent diffusion coefficient (ADC) and Fractional anisotropy (FA) values were calculated from solid enhanced part of the brain metastases. The association between FA and ADC values and histopathological subtype of the primary tumor was investigated. Results: The mean ADC and FA values obtained from the solid part of the brain metastases of SCLC were significantly lower than the NSCLC metastases (P < 0.001 and P = 0.003, respectively). ROC curve analysis showed diagnostic performance for mean ADC values (AUC=0.889, P = < 0.001) and FA values (AUC = 0.677, P = 0.002). Cut-off value of > 0.909 × 10-3 mm2/s for mean ADC (Sensitivity = 80.3, Specificity = 83.8, PPV = 89.1, NPV = 72.1) and > 0.139 for FA values (Sensitivity = 80.3, Specificity = 54.1, PPV = 74.2, NPV= 62.5) revealed in differentiating NSCLC from NSCLC. Conclusion: DTI parameters of brain metastasis can discriminate SCLC and NSCLC. ADC and FA values of metastatic brain lesions due to the lung cancer may be an important tool to differentiate histopathological subgroups. DTI may guide clinicians for the management of intracranial metastatic lesions of lung cancer.
  • Thumbnail Image
    PublicationOpen Access
    The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma.
    (2022-05-14T00:00:00Z) Topcu, Atakan; Ozturk, Akin; Yurtsever, İSMAİL; Besiroglu, Mehmet; Yasin, Ayse Irem; Turk, Haci Mehmet; Seker, Mesut; YURTSEVER, İSMAİL; TÜRK, HACI MEHMET
    Erlotinib, a tyrosine kinase inhibitor, has been shown to improve the survival of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Sarcopenia is a status with increasing importance in lung cancer, and it may predict a poor prognosis. We aimed to evaluate the impact of sarcopenia on erlotinib therapy and prognosis in patients with EGFR-mutated (exon 19 or 21 L858R) metastatic lung adenocarcinoma. Sarcopenia was defined as skeletal muscle index ≤39 cm2/m2 for women and ≤55 cm2/m2 for men. The patient characteristics, inflammation parameters, clinical and survival outcomes of the erlotinib therapy were examined according to sarcopenia status. We also analyzed the erlotinib treatment-related toxicity. Seventy-two patients were included in our retrospective study, and the mean age of the patients was 63.7 years. A total of 39 (54.2%) patients were diagnosed with sarcopenia. Patients with sarcopenia had a poor prognosis and had a shorter median progression-free survival (PFS) than patients without sarcopenia (10.5 months vs. 21.8 months, p=0.002). Sarcopenia (HR 2.08) and C-reactive protein > 6.5 mg/L (HR 2.57) were determined as independent poor prognostic factors for PFS of erlotinib therapy. Treatment-related toxicity occurred in 34.7% of patients treated with erlotinib, and sarcopenia did not significantly affect treatment-related toxicity. We also found that sarcopenia significantly affected the response to erlotinib. The expected survival outcomes may be low when erlotinib therapy is used in patients with sarcopenia and metastatic lung adenocarcinoma. This study showed that survival and clinical outcomes could be better predicted by detecting sarcopenia in patients with lung cancer using erlotinib.
  • No Thumbnail Available
    PublicationMetadata only
    Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?
    (2021-08-01T00:00:00Z) Besiroglu, Mehmet; Demir, Tarik; Shbair, Abdallah T M; Yasin, Ayse Irem; Topcu, Atakan; Turk, HACI MEHMET; TÜRK, HACI MEHMET
  • No Thumbnail Available
    PublicationMetadata only
    Is lymph node dissection necessary for staging while undergoing nephrectomy in patients with renal cell carcinoma?
    (2020-08-06T00:00:00Z) Ersöz, Cevper; Demir, Tarık; Aliyev, Altay; Beşiroğlu, Mehmet; Araz, Murat; Köstek, Osman; Sakin, Abdullah; Shbair, Abdallah T M; Çoban, Ganime; Şeker, Mesut; Türk, HACI MEHMET; ERSÖZ, CEVPER; TÜRK, HACI MEHMET
  • No Thumbnail Available
    PublicationMetadata only
    Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
    (2022-10-13T00:00:00Z) Wainberg, Zev A; Enzinger, Peter C; Kang, Yoon-Koo; Qin, Shukui; Yamaguchi, Kensei; Kim, In-Ho; Saeed, Anwaar; Oh, Sang Cheul; Li, Jin; Turk, HACI MEHMET; Teixeira, Alexandra; Borg, Christophe; Hitre, Erika; Udrea, Adrian A; Cardellino, Giovanni Gerardo; Sanchez, Raquel Guardeño; Collins, Helen; Mitra, Siddhartha; Yang, Yingsi; Catenacci, Daniel V T; Lee, Keun-Wook; TÜRK, HACI MEHMET
    Magnetic monopoles are known to emerge as leading non-perturbative fluctuations in the lattice version of non-Abelian gauge theories in some gauges. In terms of the Dirac quantization condition, these monopoles have magnetic charge |Q_M|=2. Also, magnetic monopoles with |Q_M|=1 can be introduced on the lattice via the -t Hooft loop operator. We consider the |Q_M|=1,2 monopoles in the continuum limit of the lattice gauge theories. To substitute for the Dirac strings which cost no action on the lattice, we allow for singular gauge potentials which are absent in the standard continuum version. Once the Dirac strings are allowed, it turns possible to find a solution with zero action for a monopole--antimonopole pair. This implies equivalence of the standard and modified continuum versions in perturbation theory. To imitate the nonperturbative vacuum, we introduce then a nonsingular background. The modified continuum version of the gluodynamics allows in this case for monopoles with finite non-vanishing action. Using similar techniques, we construct the -t Hooft loop operator in the continuum and predict its behavior at small and large distances both at zero and high temperatures.
  • Thumbnail Image
    PublicationOpen Access
    Breast Cancer Patients with Brain Metastases: A Cross-Sectional Study.
    (2022-08-19T00:00:00Z) Simsek, MELİH; Aliyev, Altay; Baydas, Tuba; Besiroglu, Mehmet; Demir, Tarik; Shbair, Abdallah Tm; Seker, Mesut; Turk, H Mehmet; ŞİMŞEK, MELİH; TÜRK, HACI MEHMET
    The prognosis of breast cancer patients with brain metastasis is poor. It was aimed to define the clinicopathological features of breast cancer patients with brain metastases and to determine the risk factors and survival outcomes associated with brain metastasis. This is a single-center, retrospective, cross-sectional study. A total number of 127 patients diagnosed with breast cancer and who developed brain metastasis between January 2011 and March 2021 were retrospectively analyzed. The survival and clinicopathological data of these patients according to 4 biological subtypes were evaluated (luminal A, luminal B, HER-2 overexpressing, and triple-negative). The median overall survival for all patients was 45.6 months. The median time from the diagnosis of breast cancer to the occurrence of brain metastasis was 29.7 months, and the median survival time after brain metastasis was 7.2 months. The time from the diagnosis of breast cancer to brain metastasis development was significantly shorter in HER-2 overexpressing and triple-negative subtypes than in luminal A and B subtypes. The median time from breast cancer diagnosis to brain metastasis was 33.5 months in luminal A, 40.6 months in luminal B, 16.8 months in HER-2 overexpressing, and 22.8 months in the triple-negative groups (p=0.003). We found the worst median survival after brain metastasis in the triple-negative group with 3.5 months. Early and close surveillance of high-risk patients may help early diagnosis of brain metastasis and may provide to perform effective treatments leading to longer overall survival times for this patient population.